Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by Oppenheimer Holdings Inc. in a research note issued on Sunday. They currently have a $76.00 target price on the stock. Oppenheimer Holdings Inc.’s price objective would indicate a potential upside of 23.76% from the company’s current price.
A number of other equities analysts also recently weighed in on SRPT. Piper Jaffray Cos. reissued a “sell” rating and set a $6.00 target price on shares of Sarepta Therapeutics in a research note on Saturday, June 4th. Vetr downgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong sell” rating and set a $17.28 target price for the company. in a research note on Wednesday, June 8th. JMP Securities reissued an “underperform” rating and set a $10.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, September 15th. Cowen and Company reissued a “hold” rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Finally, Wedbush reissued an “outperform” rating and set a $66.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, September 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $54.44.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 61.41 on Friday. The company’s market capitalization is $2.94 billion. The firm’s 50-day moving average is $35.91 and its 200 day moving average is $23.83. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period last year, the company earned ($0.87) EPS. Equities research analysts predict that Sarepta Therapeutics will post ($4.16) EPS for the current year.
In other news, VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the sale, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP David T. Howton sold 9,304 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $465,200.00. Following the completion of the sale, the senior vice president now directly owns 11,168 shares in the company, valued at approximately $558,400. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by insiders.
Several hedge funds have recently bought and sold shares of SRPT. Teacher Retirement System of Texas raised its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. acquired a new stake in Sarepta Therapeutics during the second quarter valued at about $154,000. Quantitative Systematic Strategies LLC acquired a new stake in Sarepta Therapeutics during the second quarter valued at about $211,000. National Planning Corp raised its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the period. Finally, First Allied Advisory Services Inc. raised its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the period. 72.09% of the stock is currently owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.